Latest news
COLL Q2 Deep Dive: ADHD Expansion and Pain Business Headwinds Shape Guidance - TradingViewTradingView · Fri, 07 Aug 2026 05:43:00 GMTCollegium Pharmaceutical, Inc. Stock 12‑Month Price Target Cut to $51.2, Implies 43% Upside - TradingViewTradingView · Thu, 06 Aug 2026 23:20:13 GMTSuperRare to Release Never Without Collection on August 10th - TradingViewTradingView · Thu, 06 Aug 2026 18:06:22 GMTCOLL: ADHD portfolio growth and AZSTARYS acquisition drive revenue and market share gains - TradingViewTradingView · Thu, 06 Aug 2026 13:23:19 GMTCollegium Pharmaceutical Q2 Earnings Call Highlights - TradingViewTradingView · Thu, 06 Aug 2026 13:04:01 GMTCOLL: Revenue growth from ADHD products offset pain segment declines; net loss driven by acquisition costs - TradingViewTradingView · Thu, 06 Aug 2026 11:35:56 GMTGOOD: Revenue, net income, and Core FFO rose in Q2 2026, with 100% rent collection and high occupancy - TradingViewTradingView · Wed, 05 Aug 2026 20:09:20 GMTCOLL Q2'26 Earnings: EPS estimate is 1.72 USD - TradingViewTradingView · Wed, 05 Aug 2026 11:01:16 GMT